Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Franchimont, Nathalie; Putzeys, V; Collette, Julien; Vermeire, Séverine; Rutgeerts, Paul; Vos, Martine De; Gossum, A. Van; Franchimont, Denis; Fiasse, René; Pelckmans, Paul; Malaise, Michel; Bélaïche, Jacques; Louis, Édouard

doi:10.1111/j.1365-2036.2004.02152.x

Cited by 77 publications

(62 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(31) Recent studies in adults with Crohn's disease have shown significant changes in biomarkers of bone metabolism with anti TNF-α therapy. (32,33) Of these, Franchimont et al reported decreased bone formation and increased bone resorption markers at baseline when compared with healthy controls. (33) The observation that bone formation was low and bone resorption was high prior to treatment with anti TNF-α therapy is consistent with our observation of low BSAP and high DPD in Crohn's disease.…”

Section: Discussionmentioning

confidence: 99%

“…(32,33) Of these, Franchimont et al reported decreased bone formation and increased bone resorption markers at baseline when compared with healthy controls. (33) The observation that bone formation was low and bone resorption was high prior to treatment with anti TNF-α therapy is consistent with our observation of low BSAP and high DPD in Crohn's disease. The observation that greater disease activity (PCDAI score) was independently associated with greater reductions in BSAP levels in our study further supports the hypothesis that inflammatory cytokines contribute to suppressed bone formation in Crohn's disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Tuchman

Thayu

Shults

et al. 2008

The Journal of Pediatrics

View full text Add to dashboard Cite

Objectives-To determine the effects of growth, maturation, and whole body bone mineral content (WB-BMC) accrual on biomarkers of bone formation [bone specific alkaline phosphatase (BSAP)] and resorption [urine deoxypyridinoline/creatinine (DPD)] in healthy children and children with Crohn's disease.Study design-BSAP and DPD were measured at baseline, and growth and dual energy x-ray absorptiometry (DXA) WB-BMC were measured at baseline and six months in 202 controls and 110 subjects with Crohn's disease, ages 5 to 21 years. Multivariable linear regression identified determinants of biomarkers in controls and subjects with Crohn's disease.Results-In controls, BSAP and DPD were significantly and independently associated with sex, Tanner stage, WB-BMC, height velocity, and WB-BMC accrual rates; these covariates explained 77-80% of the variability in bone biomarkers. Subjects with Crohn's disease had lower height-forage (p < 0.001) and WB-BMC-for-height (p < 0.05), compared with controls. Crohn's disease was associated with lower BSAP (p < 0.001) and greater DPD (p < 0.001), independent of growth, maturation, baseline WB-BMC, and WB-BMC accrual, compared with controls.Conclusions-These data illustrate the potential confounding effects of growth and WB-BMC on bone metabolism biomarkers in children. After adjustment for these effects, Crohn's disease was associated with lower biomarkers of bone formation and greater bone resorption. KeywordsCrohn's disease; height velocity; bone-specific alkaline phosphatase; urine deoxypyridinoline; dual energy x-ray absorptiometry; bone mineral content Corresponding/Reprint request author: Shamir Tuchman MD, MPH, Division of Pediatric Nephrology, Department of Pediatrics, The Children' s Hospital of Philadelphia, 34 th and Civic Center Blvd., Philadelphia, PA 19104, pH: (215) 590-2449, fax: (215) 590-3705, email: E-mail: tuchman@email.chop.edu. Edited by TW and WFB Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.The authors declare no conflicts of interest. Serum levels of biomarkers of bone formation were significantly reduced in children with newly diagnosed Crohn's disease, and biomarkers of bone resorption were variably reduced in comparison with controls; thus, bone remodeling may be suppressed in incident Crohn's disease due to a primary impairment in bone formation. (9) The accompanying editorial suggested that these findings support the use of anabolic agents as opposed to anti-resorptive agents in childhood Crohn's disease.(10) However, low overall bone mass (i.e. reduced numbers of osteoblasts and osteoclasts) and reduced ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Tuchman

Thayu

Shults

et al. 2008

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…These effects seem to be independent of whether the patients are classified as responders or non-responders to infliximab treatment based on clinical scores, and of whether the patients are on steroid therapy [16][17][18]. Patients who received infliximab have also been shown to have increased BMD based on DXA findings [21][22][23].…”

Section: Introductionmentioning

confidence: 93%

“…To date, data describing the effects of in vivo TNF-α inhibition on general bone metabolism in patients with IBD are still limited and restricted to infliximab treatment [16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease

et al. 2015

View full text Add to dashboard Cite

“…DeBoer et al [126] have shown, using a dextran sodium sulfate induced colitis model, that mice treated with anti-TNF-α antibodies demonstrated a partial normalization of pubertal timing coincident with decreased systemic inflammation. Bone metabolism is also positively affected by infliximab, at least in the short-term, manifested by improved bone formation markers [127,128].…”

Section: Biologic Treatmentmentioning

confidence: 99%

Impact of Therapeutic Strategies on Growth in Pediatric Inflammatory Bowel Disease

Shamir¹

2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Growth retardation is a common complication of pediatric inflammatory bowel disease (IBD), which may have long term effects on final adult height and carries significant social and psychological implications. Etiology may be multifactorial including undernutrition, metabolic dysregulation, inflammatory impact on hormonal growth axis and the effect of drugs such as glucocorticoids. Control of disease activity and minimizing the need for corticosteroid therapy are necessary measures in order to facilitate normal growth. However, in many cases these strategies are not sufficient. Currently, there is inconsistent evidence regarding the efficacy of available therapeutic agents to induce long-term effect on growth. The new era of biologic therapies which carries a greater potential to achieve mucosal healing, holds promise for better growth even in children with severe growth impairment. It becomes apparent that prompt recognition of growth impairment combined with aggressive tailored therapeutic approach may offer the best chance for catch-up growth. This review will discuss the definition, prevalence and mechanism of growth retardation in children with IBD and highlight the specific benefits of current therapeutic strategies.

show abstract

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Cited by 77 publications

References 58 publications

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease

Impact of Therapeutic Strategies on Growth in Pediatric Inflammatory Bowel Disease

Contact Info

Product

Resources

About